The US Food and Drug Administration (FDA) has granted clearance for Aston Sci.’s Investigational New Drug (IND) application for a Phase II clinical trial of its therapeutic cancer vaccine AST-301 (HER2-hICD vaccine).
Aston Sci. Inc., a clinical stage biopharmaceutical company specializing in clinical development of therapeutic cancer vaccines, announced that it has obtained IND approval from the US Food and Drug Administration (FDA) for phase 2 clinical trial of its main product, AST-301(HER2-hICD vaccine).
SEOUL, South Korea, Sept. 1, 2022 /PRNewswire/ -- Aston Sci. Inc., a clinical stage biopharmaceutical company specializing in clinical development of therapeutic cancer vaccines, announced that it has obtained IND approval from the U.S. Food and Drug Administration(FDA) for Phase 2 clinical trial of its main product, AST-301(HER2-hICD vaccine).